Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, ...

A groundbreaking immunotherapy is showing unprecedented success against one of the deadliest childhood brain cancers — ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

The BC Cancer Foundation is looking to raise $6.8 million to expand its provincial immunotherapy research program, a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.

Scientists rebuild the body's own proteins and fats into nano delivery vans that get genetic medicines to exactly the right ...

The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...